Clinical Trials
21
10 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1994
Active, not recruiting
2
9.5%
Completed
6
28.6%
Not yet recruiting
8
38.1%
Recruiting
5
23.8%
No approval data available
- Two Canadian clinical trials published in Nature Medicine demonstrate that fecal microbiota transplant (FMT) capsules can significantly improve cancer immunotherapy outcomes and reduce toxic side effects. - Phase II studies showed 80% response rates in lung cancer patients and 75% in melanoma patients receiving FMT plus immunotherapy, compared to 39-45% and 50-58% with immunotherapy alone, respectively. - A Phase I kidney cancer trial involving 20 patients found that customized FMT may help reduce severe colitis and diarrhea side effects that often force patients to discontinue life-sustaining immunotherapy treatment. - The advanced FMT capsules, known as LND101, are produced by Lawson Research Institute and represent a scalable approach to personalized microbiome therapy for cancer patients.
- LivaNova's comprehensive CORE-VNS study of over 800 patients worldwide demonstrates sustained effectiveness of VNS Therapy for drug-resistant epilepsy over 36 months. - The study shows 77% median reduction in generalized tonic-clonic seizures at 24 months, with 43% of participants achieving complete seizure freedom. - VNS Therapy proved effective across age groups, with early seizure reduction observed at three months and benefits maintained throughout the study period. - The real-world evidence validates VNS Therapy as an effective adjunctive treatment for patients who have failed multiple anti-seizure medications.
- Nova Southeastern University researchers have begun a clinical trial testing AstraZeneca's monoclonal antibody sipavibart as a potential treatment for Long COVID, funded by the Schmidt Initiative for Long COVID. - The double-blind, randomized controlled trial will enroll 100 patients to evaluate whether sipavibart, already approved for COVID-19 prevention in Japan and the EU, can improve cognitive dysfunction, autonomic nervous system effects, and exercise tolerance. - This trial is one of three Long COVID treatment studies launching in 2025, alongside another global study testing anti-inflammatory drugs upadacitinib and pirfenidone across seven locations on four continents.
- The phase II ORATOR trial compared radiotherapy and transoral robotic surgery for oropharyngeal squamous cell carcinoma, revealing similar oncologic outcomes at 5 years. - While overall survival and progression-free survival were comparable, the study identified differing toxicity and quality of life profiles between the two treatment approaches. - Radiotherapy was associated with higher rates of neutropenia and dry mouth, whereas transoral robotic surgery led to more dysphagia and pain. - The study emphasizes shared decision-making between patients and providers when choosing between radiotherapy and transoral robotic surgery for oropharyngeal cancer.
